Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Net Income for 10 consecutive years, with -$43.7 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 28.93% to -$43.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$230.4 million through Dec 2025, up 13.64% year-over-year, with the annual reading at -$230.4 million for FY2025, 13.64% up from the prior year.
  • Net Income hit -$43.7 million in Q4 2025 for Rocket Pharmaceuticals, up from -$52.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$33.8 million in Q2 2021 to a low of -$71.9 million in Q2 2024.
  • Historically, Net Income has averaged -$57.1 million across 5 years, with a median of -$61.2 million in 2023.
  • Biggest five-year swings in Net Income: plummeted 71.22% in 2021 and later rose 28.93% in 2025.
  • Year by year, Net Income stood at -$43.9 million in 2021, then crashed by 55.43% to -$68.3 million in 2022, then grew by 7.86% to -$62.9 million in 2023, then grew by 2.2% to -$61.6 million in 2024, then grew by 28.93% to -$43.7 million in 2025.
  • Business Quant data shows Net Income for RCKT at -$43.7 million in Q4 2025, -$52.0 million in Q3 2025, and -$71.1 million in Q2 2025.